Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10169430 | 0.83 | TDP1 (0.67) | HPGDUSP2SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL6972943 | 0.78 | ALDH1A1 (0.58) | HPGDALDH1A1TSHRMAPTPOLB | |
| SCHEMBL784749 | 0.78 | HRH4 (0.61) | SMN1; SMN2LMNAGAA | |
| SCHEMBL16222432 | 0.76 | SMN1; SMN2 (0.60) | HPGDSMN1; SMN2ALDH1A1TSHRMAPT | |
| SCHEMBL6981587 | 0.74 | GPR119 (0.59) | HPGDUSP2ALDH1A1MAPTLMNA | |
| SCHEMBL12452908 | 0.74 | HRH3 (0.50) | SMN1; SMN2ALDH1A1TSHRMAPTLMNA | |
| SCHEMBL19658409 | 0.74 | TAF1 (0.48) | HPGDUSP2SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL793101 | 0.72 | HRH4 (0.74) | — | |
| SCHEMBL3485938 | 0.72 | GPR119 (0.74) | — | |
| SCHEMBL22873583 | 0.72 | HRH4 (0.47) | HPGDUSP2SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9084828-B2 | Oligomer-protein tyrosine kinase inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2015-07-21 | — | — | US | disclosed |
| US-9084828-B2 | Oligomer-protein tyrosine kinase inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140329828-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329828-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2014-11-06 | — | — | US | disclosed |
| US-8816077-B2 | Oligomer-protein tyrosine kinase inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2014-08-26 | — | — | US | disclosed |
| US-20120071492-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329828-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | HPGD 3982/4885USP2 1491/4885SMN1; SMN2 3622/4885 |
| US-20120071492-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | HPGD 4024/4885USP2 1464/4885SMN1; SMN2 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.